2000
DOI: 10.1016/s0960-894x(00)00556-4
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72–85

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
79
0
1

Year Published

2003
2003
2011
2011

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 48 publications
(80 citation statements)
references
References 24 publications
0
79
0
1
Order By: Relevance
“…Related work in our laboratory has led to the design and synthesis of cyclic analogues for guinea pig MBP 72-85 , Thrombin receptor motif SFLLR, Angiotensins II and III, and GnRH (unpublished) which were able to maintain or suppress the biological function of the original peptide. 15,20,[23][24][25][26][27][28] We had previously demonstrated that injection of Lewis rats with linear or cyclic guinea pig MBP 72-85 peptides induced EAE. 19 15 In our in vivo rat studies, EAE was induced by the agonist guinea pig epitope MBP [72][73][74][75][76][77][78][79][80][81][82][83][84][85] and not by the human MBP 83-99 agonist peptide.…”
Section: Discussionmentioning
confidence: 99%
“…Related work in our laboratory has led to the design and synthesis of cyclic analogues for guinea pig MBP 72-85 , Thrombin receptor motif SFLLR, Angiotensins II and III, and GnRH (unpublished) which were able to maintain or suppress the biological function of the original peptide. 15,20,[23][24][25][26][27][28] We had previously demonstrated that injection of Lewis rats with linear or cyclic guinea pig MBP 72-85 peptides induced EAE. 19 15 In our in vivo rat studies, EAE was induced by the agonist guinea pig epitope MBP [72][73][74][75][76][77][78][79][80][81][82][83][84][85] and not by the human MBP 83-99 agonist peptide.…”
Section: Discussionmentioning
confidence: 99%
“…Effort must be made to understand: (a) the forces that determine the folding of the epitope; (b) the conservation of the linearity and extended structure of the altered epitope; (c) the molecular features of the altered epitope that maximize the productive interactions with HLA-DR2 and minimize the contacts with TCR. The linear peptides were prepared on 2-chlorotrityl chloride resin (CLTR-Cl) using the Fmoc/tBu solid-phase methodology [28][29][30][31]. The first N a Fmoc (9-fluorenylmethyloxycarboxyl)-protected amino acid (Fmoc-Pro-OH) was esterified to the resin in the presence of diisopropylethylamine (DIPEA) in dichloromethane (DCM) in 1 h at RT [28][29][30][31].…”
Section: Resultsmentioning
confidence: 99%
“…The linear peptides were prepared on 2-chlorotrityl chloride resin (CLTR-Cl) using the Fmoc/tBu solid-phase methodology [28][29][30][31]. The first N a Fmoc (9-fluorenylmethyloxycarboxyl)-protected amino acid (Fmoc-Pro-OH) was esterified to the resin in the presence of diisopropylethylamine (DIPEA) in dichloromethane (DCM) in 1 h at RT [28][29][30][31]. DCM/MeOH/DIPEA (85:10:5) was then added and the resulting mixture was stirred for another 10 min at RT.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations